A314130 Stock Overview
A clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Genome & Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,740.00 |
| 52 Week High | ₩7,335.00 |
| 52 Week Low | ₩3,275.00 |
| Beta | 1.04 |
| 11 Month Change | -7.77% |
| 3 Month Change | -9.55% |
| 1 Year Change | -46.91% |
| 33 Year Change | -79.89% |
| 5 Year Change | -79.92% |
| Change since IPO | -19.83% |
Recent News & Updates
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump
Sep 06
Is Genome (KOSDAQ:314130) A Risky Investment?
Jul 03Investors Still Aren't Entirely Convinced By Genome & Company's (KOSDAQ:314130) Revenues Despite 49% Price Jump
May 27Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump
Apr 11Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?
Mar 08Recent updates
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump
Sep 06Is Genome (KOSDAQ:314130) A Risky Investment?
Jul 03Investors Still Aren't Entirely Convinced By Genome & Company's (KOSDAQ:314130) Revenues Despite 49% Price Jump
May 27Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump
Apr 11Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?
Mar 08Genome (KOSDAQ:314130) Is In A Good Position To Deliver On Growth Plans
Mar 17Shareholder Returns
| A314130 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -1.3% | -0.2% | 3.8% |
| 1Y | -46.9% | 44.6% | 5.8% |
Return vs Industry: A314130 underperformed the KR Biotechs industry which returned 44.6% over the past year.
Return vs Market: A314130 underperformed the KR Market which returned 5.8% over the past year.
Price Volatility
| A314130 volatility | |
|---|---|
| A314130 Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.5% |
Stable Share Price: A314130's share price has been volatile over the past 3 months.
Volatility Over Time: A314130's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 90 | Jisoo Pae | genomecom.co.kr |
Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, cosmeceuticals, and dietary supplements.
Genome & Company Fundamentals Summary
| A314130 fundamental statistics | |
|---|---|
| Market cap | ₩114.34b |
| Earnings (TTM) | -₩37.88b |
| Revenue (TTM) | ₩23.92b |
4.8x
P/S Ratio-3.0x
P/E RatioIs A314130 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A314130 income statement (TTM) | |
|---|---|
| Revenue | ₩23.92b |
| Cost of Revenue | ₩11.72b |
| Gross Profit | ₩12.20b |
| Other Expenses | ₩50.09b |
| Earnings | -₩37.88b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.24k |
| Gross Margin | 51.00% |
| Net Profit Margin | -158.35% |
| Debt/Equity Ratio | 20.6% |
How did A314130 perform over the long term?
See historical performance and comparison